What is an FDA import alert?

An FDA import alert is an official notice that instructs FDA field personnel to detain specific imported products without physically examining each individual shipment. When a company or product is placed on an import alert, any shipment that matches the alert criteria is automatically stopped at the U.S. border and refused entry. FDA issues import alerts when it has identified a pattern of violations significant enough to justify presumptive detention of future shipments.

The mechanism behind import alerts is called Detention Without Physical Examination, or DWPE. Under DWPE, FDA does not need to inspect each arriving shipment before detaining it. The previous history of non-compliance creates a rebuttable presumption that new shipments from the same firm, facility, or product category are also non-compliant. This presumption shifts the burden to the importer: the company must affirmatively demonstrate to FDA that a specific shipment meets all applicable requirements before it can be released.

FDA maintains a public database of active import alerts on its import alert system. Companies, products, and countries can all be listed. The public nature of the list means that customers, distributors, and regulatory bodies in other countries can see a company’s import alert status.

What triggers an FDA import alert?

Import alerts are triggered by findings during FDA inspections of foreign facilities, laboratory analysis of imported samples, or recurring compliance failures identified through multiple import entries. The common triggers include cGMP violations found during FDA overseas inspections, contamination detected in imported products, adulteration or misbranding violations, and failure to register with FDA as required for specific product categories.

For pharmaceutical manufacturers, the most common path to an import alert starts with an FDA inspection of the foreign facility that uncovers systemic cGMP deficiencies, particularly in laboratory controls, data integrity, or manufacturing processes. If the facility receives a Warning Letter and fails to remediate adequately, FDA may issue an import alert covering products from that site.

For food and dietary supplement manufacturers, import alerts often follow detection of contaminated or adulterated products at the border. Once a pattern is established, FDA issues an alert covering all shipments from the firm, meaning a single contamination finding can affect an entire product line.

For medical device manufacturers, import alerts under FDA Registration failures are common. Devices that are not properly registered with FDA or that are not cleared through the appropriate premarket pathway are subject to detention.

How does DWPE affect your supply chain?

The operational impact of an import alert is immediate. Each shipment that arrives at a U.S. port of entry and matches the alert criteria receives a Notice of Detention from U.S. Customs and Border Protection or FDA. The importer then has a limited window, typically five days for food and ten days for drugs and devices, to provide testimony or evidence that the specific shipment is compliant.

If the evidence is insufficient or not submitted in time, FDA refuses admission of the shipment. The importer must then either re-export the goods, destroy them under FDA supervision, or request reconditioning if a reconditioning procedure is available for the product type.

The financial impact compounds quickly. Detention costs, freight charges for holding containers at port, laboratory testing costs for every shipment, and the cost of lost product add up. For manufacturers dependent on U.S. sales, an active import alert can be commercially devastating. Lead times extend, contracts go unfulfilled, and customers source from alternative suppliers while the import alert remains active.

How does a company get removed from an FDA import alert?

Getting removed from an import alert, referred to as being removed from the DWPE list, requires demonstrating to FDA that the conditions that caused the alert no longer exist. The specific steps vary by product type and the reason the alert was issued, but the general framework applies across categories.

The first step is a comprehensive internal assessment to identify all compliance gaps that led to the alert. This assessment must go beyond the specific observations cited by FDA. The underlying systemic failures that allowed those observations to occur must be identified and corrected.

The second step is a remediation program with documented corrective actions. For pharmaceutical manufacturers, this typically includes a full quality system assessment, written corrective action plans addressing every cited deficiency, and evidence that corrections have been implemented and verified. A root cause investigation for each cited issue must accompany the response.

The third step is an FDA inspection of the facility. FDA will typically conduct a re-inspection before removing a manufacturer from a DWPE list. The inspection must confirm that the corrective actions are in place, operating effectively, and sustainable. A facility that corrected specific observations but has an underlying quality system that cannot maintain compliance will not pass re-inspection.

After a successful re-inspection, FDA removes the facility or product from the import alert. This removal is not automatic, it requires FDA to update the alert database, and the process can take months after the inspection is complete.

Can individual shipments be released while an import alert is active?

Yes. For each detained shipment, the importer can submit evidence to overcome the presumption of non-compliance. For pharmaceutical products, this typically requires laboratory testing of the specific lot by a U.S.-accredited laboratory, demonstrating that the product meets specifications. For food products, similar third-party testing may be accepted.

This per-shipment release process is expensive and slow. It does not remove the company from the import alert list. It simply allows specific shipments to be released on their own merits. Companies that rely on this approach as a long-term strategy find that the per-shipment costs eventually outweigh the benefit, particularly if laboratory testing results are inconsistent.

What quality system failures most commonly lead to import alerts?

A review of FDA import alert history for pharmaceutical manufacturers shows that data integrity failures are the leading driver of recent alerts. Data integrity issues, including backdating records, deleting raw data, and creating duplicate audit trails, are particularly serious because they indicate the laboratory controls cannot be trusted. FDA cannot evaluate the quality of a product whose records it cannot rely on.

Laboratory OOS investigation failures appear alongside data integrity issues in many import alerts. When facilities handle OOS results by re-testing without adequate investigation, attributing failures to undefined “laboratory error,” or invalidating results without scientific justification, FDA treats this as a systemic failure of the quality system rather than an isolated incident.

Contamination events, particularly microbial contamination in sterile products or heavy metal contamination in dietary supplements, are the most common trigger for food and device import alerts.

How a validated QMS reduces import alert risk

The quality system failures that lead to import alerts share a common root: inadequate controls that allow problems to accumulate without detection. Data integrity issues often start small. An analyst re-tests an OOS result informally, and because no one is tracking the re-test in a system with an immutable record, the practice becomes routine. By the time an FDA investigator reviews the audit trail, there are dozens of undocumented re-tests and invalidated results across multiple batches.

A validated electronic QMS with a 21 CFR Part 11-compliant audit trail eliminates the conditions for data integrity failures. Every entry in the system is timestamped, attributed to a specific user, and cannot be altered without the change being captured in the trail. OOS investigation workflows enforce the required steps before any result can be invalidated. Laboratory records are complete and retrievable with a single query.

Cloudtheapp provides a fully validated, cloud-based QMS platform with 60+ applications covering laboratory management, CAPA, deviation reports, supplier quality management, document control, and more. The platform is validated under FDA’s Computer System Validation guidelines and supports the full audit trail requirements of 21 CFR Part 11. Quality teams at international manufacturers use Cloudtheapp to maintain inspection-ready documentation that meets FDA expectations for both domestic and imported product compliance.

If your organization imports regulated products into the U.S. and wants to ensure your quality system can withstand FDA scrutiny, schedule a demo with Cloudtheapp to see how the platform addresses the systemic quality gaps that drive import alerts.

What should quality teams do to prevent an import alert?

Prevention is far less costly than remediation. The quality teams that avoid import alerts treat every FDA inspection, even those that result in no observations, as a stress test of their quality system. They run internal audits that mirror FDA’s inspection approach, using the audit findings to identify gaps before an investigator does.

For laboratories, this means conducting periodic data integrity self-assessments that examine audit trails for patterns inconsistent with documented procedures. For manufacturing operations, it means verifying that batch records are completed correctly and on time, and that deviation investigations are closed with documented root causes and verified corrective actions.

For supplier quality, it means maintaining a supplier qualification program that periodically reassesses the compliance status of suppliers before problems appear in incoming product testing. A supplier that is under an import alert is one that your quality system should have flagged long before FDA did.